Short Summary
Meta Platforms has filed an IPR petition seeking to invalidate Sterling Computers' 7,716,217 patent covering email relevance scoring, citing obviousness over Dumais, Rose, and a Rose‑Bieganski combination.
Detailed Summary
In Petition IPR2025-00430, Meta Platforms, Inc. challenges claims 1‑3, 5‑9, 13‑15, 18‑19, and 22 of U.S. Patent No. 7,716,217, which describe a system for determining relevance scores of electronic content such as email. The petitioner argues that each challenged claim is obvious in view of three prior‑art references: Dumais (U.S. Pat. App. Pub. No. 2007/0016553 A1), Rose (U.S. Pat. No. 6,202,058 B1), and a combination of Rose with Bieganski (U.S. Pat. No. 6,334,127). The petition also contends that discretionary denial under §314(a) and §325(d) would be inappropriate, emphasizing the lack of a substantial relationship with other challengers and the petitioner’s first challenge of the ’217 patent. An expert declaration by Dr. Edward A. Fox supports the obviousness arguments. No claim construction is asserted, and the petition seeks institution of the IPR.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Meta Platforms, Inc. vs Sterling Computers Corporation is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLCvsSecure Communication Technologies, LLC
Google’s petition to invalidate Secure Communication Technologies’ 8,116,749 patent was denied. The Board found the petition’s anticipation and obviousness arguments based on Mgrdechian and Kulakowski insufficiently particularized, especially regarding dynamic identifiers and predetermined events.
Ascendis Pharma A/S et al.vsBioMarin Pharmaceutical Inc.
Ascendis Pharma has filed a PGR petition seeking cancellation of BioMarin’s U.S. Patent 12,331,106 covering CNP‑variant treatments for achondroplasia. The petition alleges obviousness, anticipation, lack of enablement, and an improper dependent claim. The Board must decide whether to institute the review.
Samsung Electronics Co., Ltd. et al.vsNetlist, Inc.
Samsung and Micron successfully challenged Netlist’s ’506 memory‑module patent in a PGR, resulting in all 20 claims being held unpatentable for obviousness over multiple prior‑art references.
CentralSquare Technologies, LLCvsCarbyne, Ltd. et al.
The USPTO denied Carbyne’s request for an extension to file a Director Review, finding no good cause and citing Revvo precedent. CentralSquare’s claim‑construction positions were already known before the deadline.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,077,791 covering modified PH20 hyaluronidase proteins. The petition asserts that the claims are overly broad and lack both written description and enablement under 35 U.S.C. §112(a). Merck seeks institution of the proceeding and cancellation of all claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.